Statistical analysis.
Sample sizes of 12 vaccinees and 4 controls in each age group were selected to be appropriate for the initial assessment of safety, tolerability, and immunogenicity of an investigational vaccine; a larger sample size of 20 vaccinees and 6 NS controls was selected for adults aged 18–35 years on the basis of power calculations for efficacy in a CHMI study.